Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS

New England Journal of Medicine

Volumn 334, Issue 7, 1996, Pages 426-431

  O'Brien, William A ^a,g   Hartigan, Pamela M ^b   Martin, David ^c   Esinhart, James ^d   Hill, Andrew ^d   Benoit, Sharon ^d   Rubin, Marc ^d   Simberkoff, Michael S ^e   Hamilton, John D ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Vet Aff Coop Studs Prog C   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d GLAXOSMITHKLINE   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD4 ANTIGEN; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; LIFE TABLES; OUTCOME ASSESSMENT (HEALTH CARE); REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; RNA, VIRAL; ZIDOVUDINE;

EID: 0030058515     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199602153340703     Document Type: Article

References (40)

1. Hamilton JD, Hartigan PM, Simberoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of a Veterans Affairs Cooperative Study. N Engl J Med 1992,326:437-43
2. Concorde Coordinating Committee. Concorde MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322:941-9
4. Fischl MA, Richman DD, Hansen N, et al The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial Ann Intern Med 1990,112 727-37
5. Volberding PA, Lagakos SW, Grimes JM, et al The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994,272.437-42.
6. Machado SG, Gail MH, Ellenberg SS On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr 1990,3 1063-73.
7. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
8. Valentine FT, Jacobson MA Immunological and virological surrogate markers in the evaluation of therapies for ITIV infection. AIDS 1990,4 Suppl 1. S201-S206.
9. Lagakos SW. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clin Infect Dis 1993;16:Suppl 1.S22-S25.
10. Lacey JN, Forbes MA, Waugh MA, Cooper EH, Hambling MH. Serum beta 2-microglobulin and human immunodeficiency virus infection AIDS 1987; 1:123-7
11. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dienen MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity application in HIV infection Immunol Today 1988;9 150-5.
12. Kramer A, Wiktor SZ, Fuchs D, et al. Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection J Acquir Immune Defic Syndr 1989,2.291-6
13. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defic Syndr 1989;2:70-6
14. Cunningham AL, Dwyer DE, Dowton DN Viral markers in HIV infection and AIDS. J Acquir Immune Defic Syndr 1993;6 Suppl 1:S32-S35
15. Spector SA, Kennedy C, McCutchan JA, et al. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. J Infect Dis 1989;159 822-8.
16. Nishaman P, Huskins KR, Stehn S, Detels R, Fahey JL A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 1990; 162.21-8.
17. Fiscus SA, DeGruttola V, Gupta P, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995;171:305-11.
18. Piatak M Jr, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259. 1749-54
19. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection Nature 1995;373.117-22.
20. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995,373.123-6
21. Prentice RL Surrogate endpoints in clinical trials definition and operational criteria Stat Med 1989;8.431-40.
22. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36:Suppl:1S-15S.
23. Simberkoff M, Hartigan P, Hamilton J, et al. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: report of VA Cooperative Study. J Acquit Immune Defic Syndr Hum Retrovirol 1996;11:142-50.
24. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
25. Mulder T, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma, application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
26. Cox DR, Hinkley DV Theoretical statistics. New York: Halsted Press, 1979
27. Kalbfleisch JD, Prentice RL The statistical analysis of failure time data. New York: John Wiley, 1980
28. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992;11:167-78.
29. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS Nature 1993,362.359-62.
30. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993,362:355-8.
31. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697.661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993;329 1065-72.
32. Holodmy M, Katzenstein D, Winters M, et al Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy J Acquir Immune Defic Syndr 1993; 6:366-9.
33. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995,86:1082-9.
34. Holodray M, Mole L, Winters M, Merigan TC. Diurnal and short-term stability of HIV virus load as measured by gene amplification. J Acquir Immune Defic Syndr 1994,7:363-8.
35. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion Ann Intern Med 1995; 122:573-9
36. Choi S, Lagakos SW, Schooley RT, Volberding PA CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118: 674-80.
37. Lm DY, Fischl MA, Schoenfeld DA. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 1993;12:835-42.
38. Graham NMH. Piantadosi S, Park LP, Phair JP, Rinaldo CR, Fahey JL. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time J Acquir Immune Defic Syndr 1993,6:1258-66
39. Nunberg JH, Schleif WA, Boots EJ, et al Viral resistance to human immunodeficiency virus type 1-specific pyridmone reverse transcriptase inhibitors. J Virol 1991,65:4887-92.
40. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.